ANIX (Anixa Biosciences) YoY EBITDA Growth: 16.13% (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIX Anixa Biosciences Inc ANIX
32 GF Score
Price $3.64
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences YoY EBITDA Growth?

Anixa Biosciences ANIX +0.83% 32 YoY EBITDA Growth is 16.13% as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Anixa Biosciences's YoY EBITDA Growth for the quarter that ended in Apr. 2026 was 16.13%.

Anixa Biosciences's EBITDA per Share for the three months ended in Apr. 2026 was $-0.08.

Anixa Biosciences YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences YoY EBITDA Growth Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.92 0.66 22.20 -22.03 16.90

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.89 33.04 11.22 22.86 16.13
ANIX
32GF Score
Anixa Biosciences Inc ANIX
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Anixa Biosciences's YoY EBITDA Growth for the fiscal year that ended in Oct. 2025 is calculated as:

YoY EBITDA Growth (A: Oct. 2025 )
=(EBITDA per Share (A: Oct. 2025 )-EBITDA per Share (A: Oct. 2024 ))/ | EBITDA per Share (A: Oct. 2024 ) |
=(-0.359--0.432)/ | -0.432 |
=16.90 %

Anixa Biosciences's YoY EBITDA Growth for the quarter that ended in Apr. 2026 is calculated as:

YoY EBITDA Growth (Q: Apr. 2026 )
=(EBITDA per Share (Q: Apr. 2026 )-EBITDA per Share (Q: Apr. 2025 )) / | EBITDA per Share (Q: Apr. 2025 )) |
=(-0.078--0.093)/ | -0.093 |
=16.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 16.13% mean?
Anixa Biosciences (ANIX) has a YoY EBITDA Growth of 16.13% as of Apr. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Anixa Biosciences and its competitors.
Is Anixa Biosciences' YoY EBITDA Growth too high?
Anixa Biosciences' current YoY EBITDA Growth is 16.13%. Overall, Anixa Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' YoY EBITDA Growth compare to GUTS and CBUS?
Anixa Biosciences' YoY EBITDA Growth of 16.13% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Anixa Biosciences and its competitors. Anixa Biosciences's current YoY EBITDA Growth is 16.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current YoY EBITDA Growth of 16.13%. The current YoY EBITDA Growth is 16.13%. Anixa Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current YoY EBITDA Growth is 16.13% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
32GF Score

Get the complete analysis for ANIX

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.64
Price